NKG2D upregulation sensitizes tumors to combined anti-PD1 and anti-VEGF therapy and prevents hearing loss

Journal:

Nature Communications

Published:

2026-02-11

DOI:

10.1038/s41467-026-68865-8

Affiliations:

9

Authors:

18

Go to article

Institutions	Authors	Share
Massachusetts General Hospital (MGH), United States of America (USA)	12.000000 12.000000	0.67
Stanford University School of Medicine, United States of America (USA)	3.000000	0.17
OSU Department of Pediatrics (Nationwide Children's Hospital), United States of America (USA)	2.000000	0.11
Medpace, United States of America (USA)	1.000000	0.06

Interested in Oncology and Carcinogenesis?